Cross-species comparison of the mouse data with human DLBCL transcriptomic profiles showed that the “dHET down-regulated signature” was significantly depleted in tumors carrying concurrent CREBBP/KMT2D mutations but less so in single CREBBP- or KMT2D-mutant cases, as documented by GSEA of two independent DLBCL datasets (overall, 617 samples, of which 192 GCB-DLBCL) (Fig. 3 F and G and SI Appendix, Fig. S3 D–F). The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.